Scientific Program - Headache

Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here

Section Heads: Dimos Mitsikostas, Greece & Alan Rapoport, USA
FRIDAY, MARCH 24, 2017
Hall D
Chairs: Michail Vikelis, Greece; Elliott Gross, USA
Proposition: Blocking CGRP will be safe, effective and clinically meaningful for patients with migraine and chronic migraine
Capsule: CGRP plays a crucial role in migraine pathophysiology. Small molecule CGRP antagonists and monoclonal antibodies to CGRP or its receptor are promising new therapies for the treatment of migraine
Host: Alan Rapoport, USA

Yes: Messoud Ashina, Denmark
No: Christian Lampl, Austria
Discussion and rebuttals
Proposition: Correcting the derangement in sleep architecture is sufficient to treat cluster and migraine headache without medication
Capsule: Migraineurs and cluster headache patients who do not sleep well develop more frequent and severe headaches. Would optimal sleep therapies ever be good enough to take the place of medication for the treatment of these headaches, or is sleep impairment just an epiphenomenon?
Host: Jack Schim, USA
Yes: Hans Hamburger, The Netherlands
No: Oved Daniel, Israel

Discussion and rebuttals
Chairs: Theodoros Constantinidis, Greece;
Krystyna Mitosek-Szewczyk, Poland
Debate: Structural brain changes are sufficient for accurate headache diagnosis
Capsule: Recent developments in brain scanning show significant differences between the primary headache types. Will this be sufficient or confirmatory for accurate diagnosis of headache types?
Host: Lars Edvinsson, Sweden
Yes: Anna Andreou, UK
No: Messoud Ashina, Denmark
Discussion and rebuttals

Proposition: The use of a placebo is essential in headache clinical trials
The use of placebo as a control in headache trials has been questioned when efficacious treatments are already available. How critical is the placebo in clinical trials and what about ethical considerations?
Host: Klimentini Karageorgiou, Greece
Yes: Randall Weeks, USA
No: Dimos Mitsikostas, Greece
Discussion and rebuttals

Chairs: Nikolaos Fakas, Greece; Ernesto Aycardi, USA / Colombia
Lecture: The Stigma of Migraine
Robert Shapiro, USA
Proposition: New persistent daily headache is a secondary type of headache
Capsule: New daily persistent headache is a new headache that develops within 24 hours, persists constantly and its originating details are recalled by the patient years later.
Host: K. Ravishankar, India
Yes: Rob Cowan, USA
No: Randall Weeks, USA
Discussion and rebuttals

Proposition: Medication overuse headache needs to be treated with detoxification so that preventive therapy can be effective in chronic migraine
Capsule: Medication overuse headache is usually treated with detoxification from the offending agent first. There is evidence that some treatments work even prior to detoxification.
Host: MK Chu, South Korea
Yes: K. Ravishankar, India
No: Jose Miguel Lainez, Spain
Discussion and rebuttals
Chair: Mark Braschinsky, Estonia
Proposition: The thalamus and cortex are more critical to migraine pathophysiology than the trigeminal nerve
Capsule: The thalamus and cortex, but also the trigeminal nerve, are involved in migraine pathophysiology; which area is most critical in the migraine process?
Host: Christian Lampl, Austria

Thalamus and cortex: Hayrunnisa Bolay, Turkey
Trigeminal: Lars Edvinsson, Sweden
Discussion and rebuttals
Proposition: Electrical stimulation will replace medications for the treatment of cluster headache
Capsule: Several forms of electrical stimulation have been studied for migraine and cluster. Two of them have targeted cluster headache and maybe good enough to rival medication one day.
Host: Dimos Mitsikostas, Greece
Yes: Jose Miguel Lainez, Spain
No: Hayrunnisa Bolay, Turkey

Discussion and rebuttals